Practical Effect of Sorafenib Monotherapy on Advanced Hepatocellular Carcinoma and Portal Vein Tumor Thrombosis

Background/Aims: We investigated the effects of sorafenib monotherapy on advanced hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT) in a clinical setting. Methods: In total, 143 consecutive patients with unresect-able HCC were treated with sorafenib. Among these patients, 30 pat...

Full description

Saved in:
Bibliographic Details
Published in:Gut and liver 2013-11, Vol.7 (6), p.696
Main Authors: Soung Won Jeong, Jae Young Jang, Kwang Yeun Shim, Sae Hwan Lee, Sang Gyune Kim, Sang Woo Cha, Young Seok Kim, Young Deok Cho, Hong Soo Kim, Boo Sung Kim, Kyoung Ha Kim, Jung Hoon Kim
Format: Article
Language:Korean
Subjects:
Carcinoma
hepatocellular
Portal vein
Sorafenib
Thrombosis
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background/Aims: We investigated the effects of sorafenib monotherapy on advanced hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT) in a clinical setting. Methods: In total, 143 consecutive patients with unresect-able HCC were treated with sorafenib. Among these patients, 30 patients with advanced HCC and PVTT (Vp3 or 4) were treated with sorafenib monotherapy. Results: All patients had a performance status of 1 to 2 (Eastern Cooperative On-cology Group 1/2, 20/10) and Child-Pugh class A or B (A/B, 17/13). Eleven patients had modified Union for International Cancer Control stage IVA tumors, whereas 19 had stage IVB tumors. All patients had PVTT (Vp3, 6; Vp4, 24). Following sorafenib monotherapy, three patients (10.0%) had a partial response with PVTT revascularization, and nine (30.0%) had stable disease, with a disease control rate of 33.3%. The median overall survival was 3.1 months (95% confidence interval [CI], 2.70 to 3.50), and the median progression-free survival was 2.0 months (95% CI, 1.96 to 2.05). Fatigue and hand-foot skin reactions were the most troublesome side effects. Conclusions: A limited proportion of patients with advanced HCC and PVTT exhibited a remarkable outcome af-ter sorafenib monotherapy, although the treatment results in this type of patient is extremely poor. Further studies to pre-dict good responders to personalized therapy are warranted. (Gut Liver 2013;7:696-703)
ISSN:1976-2283